NEW YORK ( TheStreet) -- Syneron Medical (Nasdaq: ELOS) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

Syneron Medical Ltd., together with its subsidiaries, engages in the research, development, marketing, and sale of aesthetic medical products worldwide. Syneron Medical has a market cap of $415.7 million and is part of the health care sector and health services industry. Shares are up 38.4% year to date as of the close of trading on Wednesday.

You can view the full Syneron Medical Ratings Report or get investment ideas from our investment research center.